celecoxib has been researched along with Liver Cirrhosis in 17 studies
Liver Cirrhosis: Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This investigation consists of a double-blind, randomized, placebo-controlled trial aimed at comparing the effects of the selective COX-2 inhibitor celecoxib (200 mg every 12 hours for a total of 5 doses) on platelet and renal function and the renal response to furosemide (40 mg intravenously) with those of naproxen (500 mg every 12 hours for a total of 5 doses) and placebo in 28 patients with cirrhosis and ascites." | 9.11 | Effects of celecoxib and naproxen on renal function in nonazotemic patients with cirrhosis and ascites. ( Arroyo, V; Clària, J; Escolar, G; Ginès, P; Jiménez, W; Kent, JD; López-Parra, M; Ruiz-Del-Arbol, L; Vucelic, B, 2005) |
| "Liver cirrhosis was induced by thioacetamide (TAA)." | 8.02 | Celecoxib ameliorates liver cirrhosis via reducing inflammation and oxidative stress along spleen-liver axis in rats. ( Gan, C; Gao, J; Huang, Z; Jia, X; Jiang, J; Liu, R; Ma, X; Su, W; Tai, Y; Tang, C; Tang, S; Wu, H; Ye, Y; Zhang, L; Zhao, C, 2021) |
| "We evaluated the effects of concurrent use of methotrexate and celecoxib on silent liver and kidney damages in rheumatoid arthritis (RA) patients." | 7.80 | Concurrent use of methotrexate and celecoxib increases risk of silent liver fibrosis in rheumatoid arthritis patients with subclinical reduced kidney function. ( Lee, SK; Lee, SW; Park, JS; Park, MC; Park, YB, 2014) |
| " We report in this study that a clinically available COX-2 inhibitor, celecoxib, exacerbates porcine serum (PS)-induced hepatic fibrosis and induces hepatocellular necrosis in an experimental liver fibrosis model." | 7.75 | Celecoxib exacerbates hepatic fibrosis and induces hepatocellular necrosis in rats treated with porcine serum. ( Li, X; Liu, H; Wei, W, 2009) |
| " This investigation consists of a double-blind, randomized, placebo-controlled trial aimed at comparing the effects of the selective COX-2 inhibitor celecoxib (200 mg every 12 hours for a total of 5 doses) on platelet and renal function and the renal response to furosemide (40 mg intravenously) with those of naproxen (500 mg every 12 hours for a total of 5 doses) and placebo in 28 patients with cirrhosis and ascites." | 5.11 | Effects of celecoxib and naproxen on renal function in nonazotemic patients with cirrhosis and ascites. ( Arroyo, V; Clària, J; Escolar, G; Ginès, P; Jiménez, W; Kent, JD; López-Parra, M; Ruiz-Del-Arbol, L; Vucelic, B, 2005) |
| "Liver cirrhosis was induced by thioacetamide (TAA)." | 4.02 | Celecoxib ameliorates liver cirrhosis via reducing inflammation and oxidative stress along spleen-liver axis in rats. ( Gan, C; Gao, J; Huang, Z; Jia, X; Jiang, J; Liu, R; Ma, X; Su, W; Tai, Y; Tang, C; Tang, S; Wu, H; Ye, Y; Zhang, L; Zhao, C, 2021) |
| "We evaluated the effects of concurrent use of methotrexate and celecoxib on silent liver and kidney damages in rheumatoid arthritis (RA) patients." | 3.80 | Concurrent use of methotrexate and celecoxib increases risk of silent liver fibrosis in rheumatoid arthritis patients with subclinical reduced kidney function. ( Lee, SK; Lee, SW; Park, JS; Park, MC; Park, YB, 2014) |
| " We report in this study that a clinically available COX-2 inhibitor, celecoxib, exacerbates porcine serum (PS)-induced hepatic fibrosis and induces hepatocellular necrosis in an experimental liver fibrosis model." | 3.75 | Celecoxib exacerbates hepatic fibrosis and induces hepatocellular necrosis in rats treated with porcine serum. ( Li, X; Liu, H; Wei, W, 2009) |
| "B cells can promote liver fibrosis, but the mechanism of B cell infiltration and therapy against culprit B cells are lacking." | 1.91 | Disruption of cholangiocyte-B cell crosstalk by blocking the CXCL12-CXCR4 axis alleviates liver fibrosis. ( Dai, W; Gao, J; Huang, Z; Tang, C; Tong, H; Yang, W; Zhang, L; Zhao, C, 2023) |
| "The animal models of liver fibrosis induced with TAA were established in rats and in intestinal epithelial-specific COX-2 knockout mice." | 1.62 | Inhibition of cyclooxygenase-2 enhanced intestinal epithelial homeostasis via suppressing β-catenin signalling pathway in experimental liver fibrosis. ( Gao, J; Ma, X; Tai, Y; Tang, C; Tang, S; Tong, H; Zhang, L; Zhao, C, 2021) |
| "Celecoxib has been explored as a possible treatment of liver fibrosis with contradictory results, depending on the model." | 1.48 | Celecoxib Does Not Protect against Fibrosis and Inflammation in a Carbon Tetrachloride-Induced Model of Liver Injury. ( Hammock, BD; Harris, TR; Hwang, SH; Imai, DM; Kodani, S; Rand, AA; Yang, J, 2018) |
| "As a result, liver fibrosis induced by TAA was significantly alleviated in the celecoxib group." | 1.43 | Inhibition of cyclooxygenase-2 alleviates liver cirrhosis via improvement of the dysfunctional gut-liver axis in rats. ( Gao, JH; Huang, ZY; Liu, R; Tai, Y; Tang, CW; Tang, SH; Tang, YM; Tong, H; Wang, CH; Wen, SL; Yan, ZP; Yang, JH; Yang, WJ; Ye, C, 2016) |
| " Long-term administration of celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, can ameliorate hepatic fibrosis." | 1.40 | Celecoxib attenuates hepatic cirrhosis through inhibition of epithelial-to-mesenchymal transition of hepatocytes. ( Gao, JH; Huang, ZY; Liu, ZX; Lu, YY; Tang, CW; Tong, H; Wen, SL; Yang, WJ, 2014) |
| "Celecoxib treatment greatly reduced the tortuous hepatic portal venules." | 1.39 | Celecoxib ameliorates portal hypertension of the cirrhotic rats through the dual inhibitory effects on the intrahepatic fibrosis and angiogenesis. ( Gao, JH; Huang, ZY; Liu, ZX; Lu, YY; Tang, CW; Tong, H; Wen, SL; Yang, WJ, 2013) |
| " The objective of this study was to evaluate the risk of upper GI adverse events associated with celecoxib and oral and parenteral non-selective NSAIDs in cirrhotic patients." | 1.38 | Non-steroidal anti-inflammatory drugs use and risk of upper gastrointestinal adverse events in cirrhotic patients. ( Chang, CH; Chen, HC; Lai, MS; Lee, YC; Lin, JW; Lin, MS, 2012) |
| "Glycogen was decreased by CCl(4), while celecoxib partially prevented and reversed this effect." | 1.36 | Antifibrotic and fibrolytic properties of celecoxib in liver damage induced by carbon tetrachloride in the rat. ( Castro-Sánchez, L; Chávez, E; Moreno, MG; Muriel, P; Salazar, EP; Segovia, J; Shibayama, M; Tsutsumi, V; Vergara, P, 2010) |
| "Celecoxib was used in the treatment of inflammation in patients with cirrhosis." | 1.35 | The anti-inflammatory effect of celecoxib does not prevent liver fibrosis in bile duct-ligated rats. ( Chan, HL; Cheung, KF; Chu, ES; Go, MY; Hui, AY; Sung, JJ; Wu, CW; Yu, J, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (29.41) | 29.6817 |
| 2010's | 8 (47.06) | 24.3611 |
| 2020's | 4 (23.53) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, L | 3 |
| Zhao, C | 4 |
| Dai, W | 1 |
| Tong, H | 5 |
| Yang, W | 1 |
| Huang, Z | 2 |
| Tang, C | 3 |
| Gao, J | 3 |
| Su, W | 2 |
| Tai, Y | 4 |
| Tang, SH | 2 |
| Ye, YT | 1 |
| Gao, JH | 4 |
| Tuo, BG | 1 |
| Tang, CW | 4 |
| Tang, S | 2 |
| Jiang, J | 1 |
| Ma, X | 2 |
| Ye, Y | 1 |
| Gan, C | 1 |
| Jia, X | 1 |
| Liu, R | 2 |
| Wu, H | 1 |
| Chang, CC | 1 |
| Lee, WS | 1 |
| Hsieh, HG | 1 |
| Chuang, CL | 1 |
| Huang, HC | 1 |
| Lee, FY | 1 |
| Lee, SD | 1 |
| Harris, TR | 1 |
| Kodani, S | 1 |
| Rand, AA | 1 |
| Yang, J | 1 |
| Imai, DM | 1 |
| Hwang, SH | 1 |
| Hammock, BD | 1 |
| Wen, SL | 3 |
| Yang, WJ | 3 |
| Lu, YY | 2 |
| Huang, ZY | 3 |
| Liu, ZX | 2 |
| Park, JS | 1 |
| Park, MC | 1 |
| Park, YB | 1 |
| Lee, SK | 1 |
| Lee, SW | 1 |
| Wang, CH | 1 |
| Yan, ZP | 1 |
| Ye, C | 1 |
| Tang, YM | 1 |
| Yang, JH | 1 |
| Liu, H | 1 |
| Wei, W | 1 |
| Li, X | 1 |
| Chávez, E | 1 |
| Segovia, J | 1 |
| Shibayama, M | 1 |
| Tsutsumi, V | 1 |
| Vergara, P | 1 |
| Castro-Sánchez, L | 1 |
| Salazar, EP | 1 |
| Moreno, MG | 1 |
| Muriel, P | 1 |
| Lee, YC | 1 |
| Chang, CH | 1 |
| Lin, JW | 1 |
| Chen, HC | 1 |
| Lin, MS | 1 |
| Lai, MS | 1 |
| Guevara, M | 1 |
| Abecasis, R | 1 |
| Terg, R | 1 |
| Clària, J | 1 |
| Kent, JD | 1 |
| López-Parra, M | 1 |
| Escolar, G | 1 |
| Ruiz-Del-Arbol, L | 1 |
| Ginès, P | 1 |
| Jiménez, W | 1 |
| Vucelic, B | 1 |
| Arroyo, V | 1 |
| Campbell, MS | 1 |
| Makar, GA | 1 |
| Yu, J | 1 |
| Hui, AY | 1 |
| Chu, ES | 1 |
| Go, MY | 1 |
| Cheung, KF | 1 |
| Wu, CW | 1 |
| Chan, HL | 1 |
| Sung, JJ | 1 |
2 trials available for celecoxib and Liver Cirrhosis
| Article | Year |
|---|---|
Effect of celecoxib on renal function in cirrhotic patients with ascites. A pilot study.
Topics: Adult; Aged; Celecoxib; Cyclooxygenase Inhibitors; Female; Humans; Kidney; Kidney Function Tests; Li | 2004 |
Effects of celecoxib and naproxen on renal function in nonazotemic patients with cirrhosis and ascites.
Topics: Ascites; Celecoxib; Dinoprostone; Double-Blind Method; Female; Furosemide; Glomerular Filtration Rat | 2005 |
15 other studies available for celecoxib and Liver Cirrhosis
| Article | Year |
|---|---|
Disruption of cholangiocyte-B cell crosstalk by blocking the CXCL12-CXCR4 axis alleviates liver fibrosis.
Topics: Animals; Celecoxib; Cell Proliferation; Chemokine CXCL12; Cyclooxygenase 2; Epithelial Cells; Humans | 2023 |
Celecoxib attenuates hepatocyte apoptosis by inhibiting endoplasmic reticulum stress in thioacetamide-induced cirrhotic rats.
Topics: Animals; Apoptosis; Celecoxib; Endoplasmic Reticulum Stress; Endoribonucleases; Hepatocytes; Liver C | 2020 |
Celecoxib ameliorates liver cirrhosis via reducing inflammation and oxidative stress along spleen-liver axis in rats.
Topics: Animals; Apoptosis; Celecoxib; China; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Hepatic S | 2021 |
Inhibition of cyclooxygenase-2 enhanced intestinal epithelial homeostasis via suppressing β-catenin signalling pathway in experimental liver fibrosis.
Topics: Animals; beta Catenin; Celecoxib; Cell Line; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Disease | 2021 |
Selective cyclooxygenase inhibition by SC-560 improves hepatopulmonary syndrome in cirrhotic rats.
Topics: Animals; Celecoxib; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Disease Models, Animal; Down-Regula | 2017 |
Celecoxib Does Not Protect against Fibrosis and Inflammation in a Carbon Tetrachloride-Induced Model of Liver Injury.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carbon Tetrachloride; Celecoxib; Collagen; Cycloox | 2018 |
Celecoxib ameliorates portal hypertension of the cirrhotic rats through the dual inhibitory effects on the intrahepatic fibrosis and angiogenesis.
Topics: Angiogenesis Inhibitors; Animals; Celecoxib; Disease Models, Animal; Hypertension, Portal; Kidney; L | 2013 |
Celecoxib attenuates hepatic cirrhosis through inhibition of epithelial-to-mesenchymal transition of hepatocytes.
Topics: Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Down-Regulation; Epithelial | 2014 |
Concurrent use of methotrexate and celecoxib increases risk of silent liver fibrosis in rheumatoid arthritis patients with subclinical reduced kidney function.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Celecoxib; Cross-Sectional Studies; Cycloo | 2014 |
Inhibition of cyclooxygenase-2 alleviates liver cirrhosis via improvement of the dysfunctional gut-liver axis in rats.
Topics: Animals; Caco-2 Cells; Cadherins; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinopros | 2016 |
Celecoxib exacerbates hepatic fibrosis and induces hepatocellular necrosis in rats treated with porcine serum.
Topics: Animals; Body Weight; Celecoxib; Chemical and Drug Induced Liver Injury; Cyclooxygenase 2 Inhibitors | 2009 |
Antifibrotic and fibrolytic properties of celecoxib in liver damage induced by carbon tetrachloride in the rat.
Topics: Alanine Transaminase; Animals; Anti-Inflammatory Agents; Antioxidants; Aspartate Aminotransferases; | 2010 |
Non-steroidal anti-inflammatory drugs use and risk of upper gastrointestinal adverse events in cirrhotic patients.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Comorbidity; Cyc | 2012 |
Safety of short-term administration of celecoxib in decompensated cirrhosis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Humans; Kidney Diseases; Liver Cirrhosis; Naprox | 2005 |
The anti-inflammatory effect of celecoxib does not prevent liver fibrosis in bile duct-ligated rats.
Topics: Alanine Transaminase; Animals; Anti-Inflammatory Agents, Non-Steroidal; Bile Ducts; Celecoxib; Inter | 2009 |